-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CT900 is a novel small molecule thymidylate synthase inhibitor that binds to the α-folate receptor (α-FR), which in turn can be selectively taken up by tumors overexpressing α-FR
The study used a 3+3 dose escalation design
A total of 109 patients were enrolled, 42 in the dose-escalation cohort and 67 in the expansion cohort
In the expansion cohort, the overall response rate (ORR) was 14/64 (21.
In summary, the recommended Phase II dose/scheme is 12 mg/m2/q2Wk
Original source:
Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang, et al.